ReviewReviews in endocrine & metabolic disorders2026
Redefining the timeline: a three-phase framework of hypothalamic microinflammation in metabolic disease.
Review in Reviews in endocrine & metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Hypothalamic neurovascular and extracellular matrix remodeling: Cellular niche orchestration of immune-metabolic adaptation to nutritional stress.Reviews in endocrine & metabolic disorders · 2026Review
- Ovarian hormones and high-fat diet duration distinctively modulate hypothalamic chemokine profile.Journal of neuroendocrinology · 2026Article
- Hypothalamic wars: the last nanodelivery.Reviews in endocrine & metabolic disorders · 2026Review
- New Adjuvant Therapies for Obesity-Related Disorders Associated with Meta-Neuroinflammation.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Tirzepatide and Metformin Effects on Hunger and BMI in an Adolescent with Hyperphagia and Severe Obesity due to MC4R Deficiency: A Case Report.Obesity facts · 2026Article
- Hypothalamic neuroimmune remodeling as an immunometabolic bridge between childhood obesity and earlier pubertal onset.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The hypothalamus plays a central role in regulating energy balance, and its dysfunction is a key contributor to the development of metabolic diseases such as obesity and type 2 diabetes. Although peripheral inflammation has been extensively studied, hypothalamic inflammation, termed hypothalamic microinflammation, has emerged as a critical early event in the pathogenesis of these diseases. This localized, moderate, yet sustained inflammatory response involves a complex interplay between different cell types, including microglia, astrocytes, neurons, and tanycytes, which exhibit temporal and dynamic changes. Hypothalamic microinflammation is triggered by various metabolic stressors, including high-fat diets, aging, and glial priming, and occurs even before peripheral tissues show signs of inflammation. In this review, we propose a conceptual framework that divides the progression of hypothalamic microinflammation into three distinct phases: the Initiation Spark, characterized by rapid inflammatory signaling; the Adaptive Transition, where compensatory mechanisms attempt to restore homeostasis; and the Dysfunctional Phase, leading to chronic inflammation and metabolic dysfunction. Despite significant progress in understanding hypothalamic inflammation, several critical questions remain, including the precise triggers of this response, the chronology of molecular and cellular events, and the reversibility of early changes. Additionally, emerging evidence suggests that sex differences influence the susceptibility and progression of hypothalamic microinflammation, further complicating our understanding. This review examines the dynamics of hypothalamic microinflammation, its impact on brain and peripheral insulin resistance, and its role in disrupting energy balance. Understanding these processes is crucial for identifying therapeutic targets and early intervention windows to prevent or reverse metabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.